Skip to main content

Advertisement

Table 1 Baseline demographic and disease characteristics of patients with psoriasis

From: Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis

Randomized patients, n 149
Age, years, Mean ± SD 46.3 ± 12.8
Sex  
  Men, n (%) 114 (76.5)
White, n (%) 133 (89.3)
Psoriasis body surface area involvement, Mean ± SD 29.5 ± 18.6
Psoriasis Area and Severity Index (PASI) score, Mean ± SD 21.3 ± 9.0
Psoriatic arthritis, n (%) 38 (25.5)
Body Mass Index (BMI), n (%)  
  N 148
  Normal (BMI <25) 29 (19.6)
  Overweight (BMI ≥25 and <30) 46 (31.1)
  Obese (BMI ≥30) 73 (49.3)
Metabolic Syndrome, n (%)a 41 (27.5)
Cigarette smoking, n (%)  
  Current 50 (33.6)
  Past or current 97 (65.1)
Relevant medical history, n (%)  
  ASCVDb 6 (4.0)
  Diabetes mellitus 21 (14.1)
  Hypertension 41 (27.5)
  Hyperlipidemia 31 (20.8)
  Family history of early ASCVD 15 (10.1)
High-density lipoprotein (HDL), n 141
  Mean ± SD 47.9 ± 12.9
  HDL <40 mg/dL, n (%) 43 (30.5)
Low-density lipoprotein, n 137
  Mean ± SD 113.1 ± 35.7
Triglycerides, n 141
  Median (IQ range) 134.0 (99.0, 182.0)
Total Cholesterol, n 141
  Mean ± SD 191.8 ± 40.0
Total Cholesterol/HDL, Mean ± SD 4.3 ± 1.4
  1. ASCVD atherosclerotic cardiovascular disease, IQ interquartile range.
  2. aMetabolic syndrome is defined using modified National Cholesterol Education Program criteria (waist circumference was replaced with BMI ≥ 30) including the presence of 3 or more of the 5 risk factors: BMI ≥ 30; fasting triglycerides ≥ 150 mg/dL; fasting HDL < 40 mg/dL (male) or HDL < 50 mg/dL (female); baseline systolic pressure ≥ 130 mmHg, baseline diastolic pressure ≥ 85 mmHg, or treatment for hypertension; fasting glucose ≥ 100 mg/dL
  3. bASCVD is defined as having a baseline medical history of myocardial infarction, coronary artery bypass, stroke, transient ischemic attack, or peripheral vascular disease